3T Biosciences

3T Biosciences is a clinical-stage immunotherapy company based in South San Francisco, developing next-generation T-cell receptor (TCR) therapeutics for solid tumors and other immune-mediated diseases. Founded in 2017 on research from K. Christopher Garcia's lab at Stanford University, the company operates its proprietary 3T-TRACE (T-Cell Receptor Antigen and Cross-reactivity Evaluation) platform, which combines high-diversity yeast-display target libraries with active machine-learning to screen billions of protein fragments and identify novel shared TCR targets and specificities. 3T has raised a $40M Series A from Westlake Village BioPartners and Lightspeed Venture Partners and has struck cancer-immunotherapy collaborations with Boehringer Ingelheim worth up to $268M in milestones. This profile was surfaced as a portfolio company of CRV and enriched into the API Evangelist network; 3T publishes no public developer API, SDK, or specification surface.

3T Biosciences is profiled on the APIs.io network. Tagged areas include Company, Biotech, Immunotherapy, Oncology, and TCR Therapeutics.

3T Biosciences’ developer surface includes engineering blog, support, and 10 more developer resources.

🌐 Visit website 📡 Source on GitHub

12.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechImmunotherapyOncologyTCR TherapeuticsCell TherapyDrug DiscoveryMachine Learning

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 12.3/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 1.3 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/3t-biosciences: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 6

The organization behind the API

Website

About

Blog

Careers

LinkedIn

Twitter

Twitter

Other 1

Properties that don't map to a standard resource type

Publications

Publications

Source (apis.yml)

aid: 3t-biosciences
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/3t-biosciences.png
name: 3T Biosciences
description: 3T Biosciences is a clinical-stage immunotherapy company based in South San Francisco, developing next-generation
  T-cell receptor (TCR) therapeutics for solid tumors and other immune-mediated diseases. Founded in 2017 on research from
  K. Christopher Garcia's lab at Stanford University, the company operates its proprietary 3T-TRACE (T-Cell Receptor Antigen
  and Cross-reactivity Evaluation) platform, which combines high-diversity yeast-display target libraries with active machine-learning
  to screen billions of protein fragments and identify novel shared TCR targets and specificities. 3T has raised a $40M Series
  A from Westlake Village BioPartners and Lightspeed Venture Partners and has struck cancer-immunotherapy collaborations with
  Boehringer Ingelheim worth up to $268M in milestones. This profile was surfaced as a portfolio company of CRV and enriched
  into the API Evangelist network; 3T publishes no public developer API, SDK, or specification surface.
url: https://raw.githubusercontent.com/api-evangelist/3t-biosciences/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- crv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-17'
tags:
- Company
- Biotech
- Immunotherapy
- Oncology
- TCR Therapeutics
- Cell Therapy
- Drug Discovery
- Machine Learning
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://3tbiosciences.com/
- type: About
  url: https://3tbiosciences.com/about/
- type: Blog
  url: https://3tbiosciences.com/news/
- type: Publications
  url: https://3tbiosciences.com/publications/
- type: Careers
  url: https://3tbiosciences.com/careers/
- type: Support
  url: https://3tbiosciences.com/contact/
- type: PrivacyPolicy
  url: https://3tbiosciences.com/privacy-policy
- type: TermsOfService
  url: https://3tbiosciences.com/terms-of-service
- type: LinkedIn
  url: https://www.linkedin.com/company/3tbiosciences/
- type: Twitter
  url: https://twitter.com/3tbio
- type: LLMsTxt
  url: llms/3t-biosciences-llms.txt
- type: DomainSecurity
  url: security/3t-biosciences-domain-security.yml
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence